New hope for women with recurring cervical cancer: drug combo targets HER2-positive tumors
NCT ID NCT07172217
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tests a combination of three drugs (disitamab vedotin, iparomlimab, and tuvonralimab) in 33 women with HER2-expressing cervical cancer that has returned after first-line treatment. The goal is to see if the combination can shrink tumors or slow disease progression. Participants will be monitored for side effects and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qilu Hospital of Shandong University
Ji'an, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.